US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Array Digital Infrastructure Inc.

36.66

+0.66001.83%

Post-market: 36.660.00000.00%19:54 EDT

Volume:154.59K

Turnover:5.68M

Market Cap:3.17B

PE:5.93

High:37.20

Open:35.91

Low:35.91

Close:36.00

52wk High:60.82

52wk Low:33.71

Shares:86.38M

Float Shares:15.56M

Volume Ratio:0.79

T/O Rate:0.99%

Dividend:- -

Dividend Rate:- -

EPS(TTM):6.19

EPS(LYR):0.5551

ROE:22.68%

ROA:0.02%

PB:2.50

PE(LYR):66.05

Loading ...

Overview Company News Filings

TDS offers all-stock deal to buy remaining Array Digital shares at 0.86 exchange ratio

Telephone and Data Systems Inc: Transaction Is Expected to Qualify as a Tax-Free Reorganization

THOMSON REUTERS

Telephone and Data Systems : Under Terms of Proposal, Each Array Common Share Not Owned by Tds Would Be Exchanged for 0.86 of a Tds Common Share

THOMSON REUTERS

Telephone and Data Systems Inc: Tds Does Not Intend to Sell or Otherwise Transfer Its Interest in Array

THOMSON REUTERS

Telephone and Data Systems Announces Proposal to Acquire Public Shares of Array Digital Infrastructure

THOMSON REUTERS

Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer’s Disease

Press Release: Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights

Celldex Reports First Quarter Financial Results and Provides Corporate Update

Voyager Reports First Quarter 2026 Financial and Operating Results

Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update

Array Digital Infrastructure Inc expected to post earnings of $1.14 a share - Earnings Preview

BlockchAIn Digital Infrastructure to present at LD Micro Invitational Conference

Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026

Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026

Array Digital Infrastructure to report quarterly results, host webcast conference call

INmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7th

Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update

Blockchain Digital Infrastructure announces annual shareholder meeting

Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/AD/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AD\",,,,,undefined,":{"symbol":"AD","market":"US","secType":"STK","nameCN":"Array Digital Infrastructure Inc.","latestPrice":36.66,"timestamp":1788206400000,"preClose":36,"halted":0,"volume":154590,"hourTrading":{"tag":"盘后","latestPrice":36.66,"preClose":36.66,"latestTime":"19:54 EDT","volume":5480,"amount":200912.0476,"timestamp":1788220498455,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.01833333333333324,"floatShares":15563300,"shares":86379877,"eps":6.185934,"marketStatus":"Not Yet Opened","change":0.66,"latestTime":"08-31 16:00:00 EDT","open":35.91,"high":37.2,"low":35.91,"amount":5676563.81457,"amplitude":0.035833,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":6.185934,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788249600000},"marketStatusCode":0,"adr":0,"exchange":"NYSE","adjPreClose":36,"preHourTrading":{"tag":"盘前","latestPrice":35.91,"preClose":36,"latestTime":"09:20 EDT","volume":2,"amount":71.82,"timestamp":1788182405538,"change":-0.09,"changeRate":-0.0025,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":36.66,"preClose":36.66,"latestTime":"19:54 EDT","volume":5480,"amount":200912.0476,"timestamp":1788220498455,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.789018,"impliedVol":0.2655,"impliedVolPercentile":0.32},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AD\",,,,,undefined,":{"symbol":"AD","floatShares":15563300,"roa":"0.02%","roe":"22.68%","lyrEps":0.555055,"volumeRatio":0.789018,"shares":86379877,"dividePrice":0,"high":37.2,"amplitude":0.035833,"preClose":36,"low":35.91,"week52Low":33.71,"pbRate":"2.50","psRate":"14.83","week52High":60.82,"institutionHeld":0.3358,"latestPrice":36.66,"eps":6.185934,"divideRate":0,"volume":154590,"delay":0,"ttmEps":6.185934,"open":35.91,"prevYearClose":53.62,"prevWeekClose":36,"prevMonthClose":34.84,"prevQuarterClose":36.26,"fiveDayClose":35.59,"twentyDayClose":35,"sixtyDayClose":51.95,"dividendPayoutRate":40.52599213795753,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0.4274298457535774},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-07","symbol":"AD","fiscalQuarterEnding":"2026/06","expectedEps":0.27,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786075200000,"reportTimeType":"pre","actualEps":0.44},{"date":"2026-06-11","symbol":"AD","amount":11,"announcedDate":"2026-06-01","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-11","defaultRemindTime":1781184600000,"name":"Array Digital Infrastructure Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-25","payableDate":"2026-06-11","currency":"USD","dateTimestamp":1781150400000,"payDate":"2026-06-25"},{"market":"US","date":"2026-05-08","symbol":"AD","fiscalQuarterEnding":"2026/03","expectedEps":-0.06,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778212800000,"reportTimeType":"pre","actualEps":0.42},{"market":"US","date":"2026-02-20","symbol":"AD","fiscalQuarterEnding":"2025/12","expectedEps":0.32,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1771563600000,"reportTimeType":"pre","actualEps":0.48},{"date":"2026-01-23","symbol":"AD","amount":10.25,"announcedDate":"2026-01-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-01-23","defaultRemindTime":1769178600000,"name":"Array Digital Infrastructure Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-02-02","payableDate":"2026-01-23","currency":"USD","dateTimestamp":1769144400000,"payDate":"2026-02-02"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AD\",market:\"US\",,,undefined,":[{"executeDate":"2025-08-20","recordDate":"2025-08-11","paymentDate":"2025-08-19","value":23,"currency":"USD"},{"executeDate":"2026-01-23","recordDate":"2026-01-23","paymentDate":"2026-02-02","value":10.25,"currency":"USD"},{"executeDate":"2026-06-11","recordDate":"2026-06-11","paymentDate":"2026-06-25","value":11,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2,"buy":0.2,"hold":0.6,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.2,"analysts":5,"updateTime":1786420800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AD","date":"2026-08-28","current":5.926348,"percent":0.264368,"low":-273.92211,"twenty":-175.579899,"median":21.315684,"eighty":260.358869,"high":320.844562,"avg":59.067045,"sd":172.559501,"marketCap":3069139710},"quantilePoints":[{"date":"2025-08-15","current":-273.850129,"twenty":-273.893318,"median":-273.850129,"eighty":-273.612593,"marketCap":6572403103},{"date":"2025-08-22","current":-200.933798,"twenty":-273.763753,"median":-273.490226,"eighty":-228.502362,"marketCap":4822411161},{"date":"2025-08-29","current":-194.49692,"twenty":-273.591,"median":-200.933798,"eighty":-194.626488,"marketCap":4667926077},{"date":"2025-09-05","current":-189.890035,"twenty":-273.511821,"median":-195.360711,"eighty":-192.519268,"marketCap":4557360841},{"date":"2025-09-12","current":-184.671298,"twenty":-272.73443,"median":-194.119011,"eighty":-189.199003,"marketCap":4432111159},{"date":"2025-09-19","current":-175.349555,"twenty":-256.070925,"median":-192.368109,"eighty":-183.778715,"marketCap":4208389313},{"date":"2025-09-26","current":-169.950862,"twenty":-200.271577,"median":-189.74607,"eighty":-179.092649,"marketCap":4078820677},{"date":"2025-10-03","current":-180.892213,"twenty":-197.170296,"median":-184.671298,"eighty":-177.638601,"marketCap":4341413113},{"date":"2025-10-10","current":-180.028422,"twenty":-195.252737,"median":-184.059446,"eighty":-177.861746,"marketCap":4320682131},{"date":"2025-10-17","current":-179.200623,"twenty":-194.756057,"median":-183.555568,"eighty":-177.18511,"marketCap":4300814940},{"date":"2025-10-24","current":-177.581015,"twenty":-194.345757,"median":-180.586287,"eighty":-177.242697,"marketCap":4261944349},{"date":"2025-10-31","current":-176.105372,"twenty":-193.617663,"median":-180.892213,"eighty":-177.242697,"marketCap":4226528922},{"date":"2025-11-07","current":-171.642452,"twenty":-192.972746,"median":-180.010426,"eighty":-176.702827,"marketCap":4119418849},{"date":"2025-11-14","current":241.378582,"twenty":-192.09564,"median":-179.920448,"eighty":-175.407141,"marketCap":3917333000},{"date":"2025-11-21","current":240.473745,"twenty":-190.782619,"median":-179.452562,"eighty":-172.916544,"marketCap":3902648400},{"date":"2025-11-28","current":261.764027,"twenty":-189.890035,"median":-179.056658,"eighty":-170.850644,"marketCap":4248168400},{"date":"2025-12-05","current":265.117247,"twenty":-189.602105,"median":-178.588771,"eighty":240.420519,"marketCap":4302587800},{"date":"2025-12-12","current":265.543053,"twenty":-189.098227,"median":-177.958923,"eighty":244.409875,"marketCap":4309498200},{"date":"2025-12-19","current":274.059166,"twenty":-184.671298,"median":-177.329076,"eighty":249.043083,"marketCap":4447706200},{"date":"2025-12-26","current":286.620433,"twenty":-184.613712,"median":-177.149119,"eighty":260.390804,"marketCap":4651563000},{"date":"2026-01-02","current":285.396241,"twenty":-184.556126,"median":-176.681232,"eighty":261.913059,"marketCap":4631695600},{"date":"2026-01-09","current":277.199482,"twenty":-183.965869,"median":-175.78145,"eighty":263.648217,"marketCap":4498670400},{"date":"2026-01-16","current":297.372025,"twenty":-183.569965,"median":-174.161842,"eighty":266.266922,"marketCap":4826050600},{"date":"2026-01-23","current":320.844562,"twenty":-183.555568,"median":-173.981886,"eighty":271.994008,"marketCap":5206986400},{"date":"2026-01-30","current":252.1834,"twenty":-183.238845,"median":-172.02036,"eighty":268.321434,"marketCap":4092684400},{"date":"2026-02-06","current":257.665648,"twenty":-182.648588,"median":-169.950862,"eighty":267.224985,"marketCap":4181655800},{"date":"2026-02-13","current":269.109175,"twenty":-182.115917,"median":238.717297,"eighty":267.224985,"marketCap":4367372800},{"date":"2026-02-20","current":267.938209,"twenty":-181.48247,"median":240.926164,"eighty":268.704659,"marketCap":4348369200},{"date":"2026-02-27","current":255.643071,"twenty":-181.064971,"median":244.409875,"eighty":267.842403,"marketCap":4148831400},{"date":"2026-03-06","current":262.668864,"twenty":-180.769843,"median":247.365175,"eighty":267.342081,"marketCap":4262853000},{"date":"2026-03-13","current":255.643071,"twenty":-180.229973,"median":249.043083,"eighty":266.671437,"marketCap":4148831400},{"date":"2026-03-20","current":82.941723,"twenty":-180.021224,"median":248.376453,"eighty":265.819826,"marketCap":4043906649},{"date":"2026-03-27","current":82.498564,"twenty":-179.985233,"median":245.210832,"eighty":265.628214,"marketCap":4022299967},{"date":"2026-04-02","current":84.413012,"twenty":-179.95644,"median":244.199544,"eighty":265.543053,"marketCap":4115640834},{"date":"2026-04-10","current":87.513828,"twenty":-179.920448,"median":240.447132,"eighty":265.117247,"marketCap":4266824209},{"date":"2026-04-17","current":87.691125,"twenty":-179.920448,"median":236.588268,"eighty":264.265636,"marketCap":4275468504},{"date":"2026-04-24","current":86.627343,"twenty":-179.596527,"median":87.806368,"eighty":264.052733,"marketCap":4223602732},{"date":"2026-05-01","current":88.098909,"twenty":-179.308596,"median":87.655666,"eighty":263.999507,"marketCap":4295350384},{"date":"2026-05-08","current":87.40745,"twenty":-179.200623,"median":87.575882,"eighty":263.414024,"marketCap":4261637632},{"date":"2026-05-15","current":21.135166,"twenty":-178.912692,"median":87.337865,"eighty":263.147896,"marketCap":4402539647},{"date":"2026-05-22","current":21.338509,"twenty":-178.876701,"median":86.919883,"eighty":263.041444,"marketCap":4444896694},{"date":"2026-05-29","current":21.222313,"twenty":-178.646357,"median":86.396857,"eighty":262.74338,"marketCap":4420692667},{"date":"2026-06-05","current":21.55845,"twenty":-178.444805,"median":85.972934,"eighty":262.32822,"marketCap":4490711460},{"date":"2026-06-12","current":16.645033,"twenty":-178.17847,"median":85.475751,"eighty":262.157897,"marketCap":3467226884},{"date":"2026-06-18","current":16.18855,"twenty":-177.926531,"median":85.370237,"eighty":262.136607,"marketCap":3372139635},{"date":"2026-06-26","current":14.893798,"twenty":-177.667394,"median":85.086615,"eighty":261.913059,"marketCap":3102437619},{"date":"2026-07-02","current":15.151088,"twenty":-177.480239,"median":84.907561,"eighty":261.764027,"marketCap":3156032250},{"date":"2026-07-10","current":14.416565,"twenty":-177.285886,"median":83.339562,"eighty":261.593705,"marketCap":3003028221},{"date":"2026-07-17","current":14.495412,"twenty":-177.192309,"median":82.498564,"eighty":261.253061,"marketCap":3019452383},{"date":"2026-07-24","current":14.184174,"twenty":-177.005154,"median":82.259257,"eighty":261.061448,"marketCap":2954620167},{"date":"2026-07-31","current":14.516162,"twenty":-176.767611,"median":81.532476,"eighty":260.944352,"marketCap":3023774530},{"date":"2026-08-07","current":14.794201,"twenty":-176.56606,"median":80.513209,"eighty":260.8379,"marketCap":3081691310},{"date":"2026-08-14","current":5.765224,"twenty":-176.069381,"median":21.824041,"eighty":260.742094,"marketCap":3087300300},{"date":"2026-08-21","current":5.739385,"twenty":-175.867829,"median":21.55845,"eighty":260.635642,"marketCap":3073463660},{"date":"2026-08-28","current":5.731311,"twenty":-175.579899,"median":21.315684,"eighty":260.358869,"marketCap":3069139710}],"updateTime":1788208297655},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AD\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2633430106","title":"TDS offers all-stock deal to buy remaining Array Digital shares at 0.86 exchange ratio","url":"https://stock-news.laohu8.com/highlight/detail?id=2633430106","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633430106?lang=en_us&edition=fundamental","pubTime":"2026-05-08 19:02","pubTimestamp":1778238175,"startTime":"0","endTime":"0","summary":"TDS proposed an all-stock merger to buy remaining Array Digital Infrastructure common shares it does not already own.Offer terms set exchange at 0.86 of a TDS common share for each Array common share not owned by TDS.Exchange ratio assumes previously announced spectrum license sales close before deal completion.Proposal also assumes Array pays a USD 10.40 per-share dividend before closing, about USD 900 million in aggregate.Array formed a special committee of independent directors to evaluate proposal.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TDS - Telephone and Data Systems Inc. published the original content used to generate this news brief on May 08, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nNDL2qYcq6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TDS","BK4132","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633950430","title":"Telephone and Data Systems Inc: Transaction Is Expected to Qualify as a Tax-Free Reorganization","url":"https://stock-news.laohu8.com/highlight/detail?id=2633950430","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633950430?lang=en_us&edition=fundamental","pubTime":"2026-05-08 19:00","pubTimestamp":1778238009,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nFWN41L10D:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TDS","AD","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633606430","title":"Telephone and Data Systems : Under Terms of Proposal, Each Array Common Share Not Owned by Tds Would Be Exchanged for 0.86 of a Tds Common Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2633606430","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633606430?lang=en_us&edition=fundamental","pubTime":"2026-05-08 19:00","pubTimestamp":1778238009,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nFWN41L10D:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AD","BK4132","TDS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633309734","title":"Telephone and Data Systems Inc: Tds Does Not Intend to Sell or Otherwise Transfer Its Interest in Array","url":"https://stock-news.laohu8.com/highlight/detail?id=2633309734","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633309734?lang=en_us&edition=fundamental","pubTime":"2026-05-08 19:00","pubTimestamp":1778238009,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nFWN41L10D:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TDS","BK4132","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633306754","title":"Telephone and Data Systems Announces Proposal to Acquire Public Shares of Array Digital Infrastructure","url":"https://stock-news.laohu8.com/highlight/detail?id=2633306754","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633306754?lang=en_us&edition=fundamental","pubTime":"2026-05-08 19:00","pubTimestamp":1778238009,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nFWN41L10D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TDS","AD","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633482746","title":"Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2633482746","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633482746?lang=en_us&edition=fundamental","pubTime":"2026-05-08 14:30","pubTimestamp":1778221800,"startTime":"0","endTime":"0","summary":"TOKYO and CAMBRIDGE, Mass., May  08, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has extended the review pe","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/08/3290827/0/en/Update-on-FDA-Priority-Review-of-LEQEMBI-IQLIK-lecanemab-irmb-Subcutaneous-Injection-as-a-Starting-Dose-for-Early-Alzheimer-s-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","BK4588","MCI","ARIA","LABU","BK4585","AD","CAA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633179889","title":"Press Release: Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2633179889","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633179889?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:05","pubTimestamp":1778184300,"startTime":"0","endTime":"0","summary":"-- Phase 2b top-line data from EVO756 in chronic spontaneous urticaria  and atopic dermatitis  on track for June 2026 and 3Q26, respectively, with enrollment complete in both trials. -- Phase 2b clinical trial evaluating a subcutaneous formulation of EVO301 in AD planned, following positive proof-of-concept  data reported in February 2026. -- Plans to initiate a Phase 2b dose-ranging clinical trial of EVO756 in migraine prophylaxis in mid-2026. PALO ALTO, Calif. & NEW YORK----May 07, 2026--. Evommune, Inc.  , a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the first quarter ended March 31, 2026, and provided a business update.--  Upcoming Phase 2b Top-Line Data Readout in CSU: Enrollment is complete. in a Phase 2b dose-ranging clinical trial  in moderate-to-severe. AD patients and the Company expects to report top-line results in the. Development Program: The Company r","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","SID","EVMN","BK4006","BK4139","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633176460","title":"Celldex Reports First Quarter Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2633176460","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633176460?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:01","pubTimestamp":1778184060,"startTime":"0","endTime":"0","summary":"Enrollment completed six months ahead of guidance in both barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2); Topline data expected in Q4 26; BLA submission planned for 2","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3290499/24180/en/Celldex-Reports-First-Quarter-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4096","CLDX","BK4132","TSLP","BK4156","AD","PN","BK4175","POM","AEC","SD","BK4139","BK4213"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633176454","title":"Voyager Reports First Quarter 2026 Financial and Operating Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2633176454","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633176454?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:01","pubTimestamp":1778184060,"startTime":"0","endTime":"0","summary":"- VY1706 and NBIB-‘233 completed IND-enabling GLP toxicology; clinical entry expected H2 2026 - - Multiple presentations at ASGCT 2026, including late breaker on VY1706 3-month GLP tox data - - Ended ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3290505/36461/en/Voyager-Reports-First-Quarter-2026-Financial-and-Operating-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","IND","BK4130","BK4539","BK4132","BK4590","GLP","FA","AD","BK4144"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633414538","title":"Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2633414538","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633414538?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:00","pubTimestamp":1778151600,"startTime":"0","endTime":"0","summary":"KOASTAL-2 and -3 studies evaluating navacaprant in major depressive disorder on track for joint topline readout in the second quarter of 2026 Progressing NMRA-511 in Alzheimer’s disease agitation and ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3289792/0/en/Neumora-Therapeutics-Reports-First-Quarter-2026-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NMRA","BK4007","AD","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633145354","title":"Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2633145354","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633145354?lang=en_us&edition=fundamental","pubTime":"2026-05-07 18:59","pubTimestamp":1778151540,"startTime":"0","endTime":"0","summary":"- Full Top Line Results from Phase 1a SAD/MAD Trial of ATI-052 Exceed Aclaris’ Target Profile, Validating Potential Best-in-Class Potency Advantage and Opportunity for Extended Dosing - - Unique Dual ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3289773/37216/en/Aclaris-Therapeutics-Reports-First-Quarter-2026-Financial-Results-and-Provides-Corporate-and-Clinical-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AD","PK","BSA","BK4181","IND","ACRS","LU1169590202.USD","LU1169589451.USD","BK4218","PD","BK4023","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633351301","title":"Array Digital Infrastructure Inc  expected to post earnings of $1.14 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2633351301","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633351301?lang=en_us&edition=fundamental","pubTime":"2026-05-06 20:56","pubTimestamp":1778072166,"startTime":"0","endTime":"0","summary":"Array Digital Infrastructure Inc  expected to post earnings of $1.14 a share - Earnings Preview Array Digital Infrastructure Inc AD.N, AD is expected to  show a fall in quarterly revenue when it repor","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nL8N41J209:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TDS","BK4132","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633133401","title":"BlockchAIn Digital Infrastructure to present at LD Micro Invitational Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2633133401","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633133401?lang=en_us&edition=fundamental","pubTime":"2026-05-06 20:33","pubTimestamp":1778070784,"startTime":"0","endTime":"0","summary":"Blockchain Digital Infrastructure to attend LD Micro Invitational Conference in Los Angeles, May 17-19, 2026.Management presentation scheduled for May 19, 2026 at 2:30 p.m. PT.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDLNPSCb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU0314104364.USD","TDS","IE00BKPKM429.USD","IE00BN0W2V16.EUR","AIB","BK4132","BK4023","LU2210149790.SGD","IE00B64PRP62.GBP","LU2210150020.SGD","AD","SG9999014005.SGD","LU2095319765.USD","SG9999014021.USD","IE00BGHQF748.EUR","NDAQ","BK4116","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","BK4585","BK4588","IE00B3QW5Z07.USD","SG9999014039.USD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633247559","title":"Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2633247559","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633247559?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:15","pubTimestamp":1778012100,"startTime":"0","endTime":"0","summary":"MIAMI, May  05, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-relat","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/05/3288288/0/en/Longeveron-to-Report-2026-First-Quarter-Financial-Results-and-Host-Conference-Call-on-May-13-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4181","BK4585","BK4150","HST","LGVN","BK4132","AD","BK4218","MSC","BK4588","BK4575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633925076","title":"Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2633925076","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633925076?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:00","pubTimestamp":1778011200,"startTime":"0","endTime":"0","summary":"NEWTON, Mass., May  05, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/05/3288191/0/en/Acumen-Pharmaceuticals-to-Report-First-Quarter-Financial-Results-on-May-12-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","ABOS","AD","BK4139","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632614972","title":"Array Digital Infrastructure to report quarterly results, host webcast conference call","url":"https://stock-news.laohu8.com/highlight/detail?id=2632614972","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632614972?lang=en_us&edition=fundamental","pubTime":"2026-05-01 20:18","pubTimestamp":1777637905,"startTime":"0","endTime":"0","summary":"Array Digital Infrastructure will release first-quarter results May 8, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Array Digital Infrastructure Inc. published the original content used to generate this news brief on May 01, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nNDL38wXsy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","TDS","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631634650","title":"INmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7th","url":"https://stock-news.laohu8.com/highlight/detail?id=2631634650","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631634650?lang=en_us&edition=fundamental","pubTime":"2026-04-30 20:00","pubTimestamp":1777550400,"startTime":"0","endTime":"0","summary":"Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, April  30, 2026 (GLOBE NEWSWIRE) --  INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage infl","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/30/3284769/0/en/INmune-Bio-Inc-to-Report-First-Quarter-2026-Financial-Results-and-Provide-Corporate-Update-on-Thursday-May-7th.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INMB","BK4132","BK4139","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631636287","title":"Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2631636287","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631636287?lang=en_us&edition=fundamental","pubTime":"2026-04-30 19:00","pubTimestamp":1777546800,"startTime":"0","endTime":"0","summary":"KT-621 (STAT6) parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively FDA granted Fast Track designation to K","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/30/3284687/0/en/Kymera-Therapeutics-Announces-First-Quarter-2026-Financial-Results-and-Provides-a-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4096","BPH","IBD","EASI","BK4588","ATS","LU0006061336.USD","SID","LU1162221912.USD","BK4201","RA","LU0162691827.USD","AD","PN","BK4585","LU0072461881.USD","LU0320765646.SGD","BK4139","BK4006","LU1829250122.USD","BP","BK4132","BK4161","KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631529168","title":"Blockchain Digital Infrastructure announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2631529168","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631529168?lang=en_us&edition=fundamental","pubTime":"2026-04-30 04:33","pubTimestamp":1777494784,"startTime":"0","endTime":"0","summary":"Blockchain Digital Infrastructure will hold a virtual annual stockholders meeting via live webcast on June 16, 2026.Shareholders will vote on election of two Class I directors, with Daniel Nelson and Hongfei Zhang nominated.Meeting will also consider ratification of Carr, Riggs & Ingram as independent registered public accounting firm for fiscal years 2025 and 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Blockchain Digital Infrastructure Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 29, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL4RJvYh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AD","TDS","AIB","BK4023","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631525928","title":"Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2631525928","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631525928?lang=en_us&edition=fundamental","pubTime":"2026-04-30 04:05","pubTimestamp":1777493100,"startTime":"0","endTime":"0","summary":"--Independent data monitoring committee (IDMC) determined the trial unlikely to meet primary endpoint – --Alector remains focused on advancing its pipeline of novel ABC-enabled candidates, including a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/29/3284236/0/en/Alector-to-Discontinue-Phase-2-PROGRESS-AD-Trial-of-Nivisnebart-AL101-GSK4527226-in-Early-Alzheimer-s-Disease-Following-Interim-Futility-Analysis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169590202.USD","IND","BK4132","BK4023","PD","LU1169589451.USD","AD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":200,"code":"91000000","status":"200"}]}}